Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

    loading  Checking for direct PDF access through Ovid


The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4+ T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4+ T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.

    loading  Loading Related Articles